DREADD
Designer receptors exclusively activated by designer drugs (DREADDs) are genetically engineered GPCRs that are activated by physiologically inert synthetic small molecules (designer drugs) but not their endogenous ligand. Read our DREADDs mini-review or for practical advice on using these ligands in the lab see Stability of Water-Soluble DREADD Ligands in Solution: A Technical Review and Clozapine N-Oxide (freebase) - a technical review on stability, solubility and use in the lab).
Mianserin hydrochloride (HB1658)
Description:Non-selective 5-HT2 receptor antagonist. Shows activity at other receptors.
Purity:>99%
-
Mifepristone (HB2783)
Description:Potent glucocorticoid and progesterone receptor antagonist. Also used for gene editing as a mifepristone inducible Cas9 and Cpf1 CRISPR effector.
Purity:>99%
-
(-)-MK 801 maleate (HB0003)
Description:NMDA receptor antagonist. Less active enantiomer of (+)-MK 801.
Purity:>99%
-
(+)-MK 801 maleate (HB0004)
Description:Potent, selective, non-competitive NMDA receptor antagonist
Purity:>98%
- Description:
Novel caged, fast-equilibrating glutamate receptor antagonist. Suitable for use as a synaptic probe.
Purity:>98%
-
MPEP hydrochloride (HB0426)
Description:Potent, selective mGluR5 antagonist / mGluR4 positive allosteric modulator
Purity:>98%
-
-
MRS 2179 ammonium salt (HB4241)
Description:Selective P2Y1 antagonist. Inhibits platelet aggregation.
Purity:>98%
